Vision peripheral

Dizziness, pruritus, nervousness, asthenia, diarrhea, abdominal cramps, flatulence, tinnitus, blurred vision, peripheral edema and fluid retention... 

Rash acne slight enlargement of the thyroid gland nausea diarrhea cramps anal pruritus optic atrophy loss of vision peripheral neuropathy after prolonged use in high dosage (for months) iodine sensitivity Ivermectin... 

Damage to optic nerve/ganglion cehs Affecting central vision Affecting peripheral vision Peripheral neuropathy... 

Rods are long and thin, and are more concentrated towards the periphery of the retina. As seen in Fig. 5.2, the maximum density is at 25° eccentricity, and decreases towards the outer edges of the retina. Rods only have one type of photopigment and can therefore only detect differences in luminance (i.e. these see only in monochrome). During night-time, when illumination is low and the iris wide open, the rods are used for vision (called scotopic vision). Peripheral vision in a dark environment is much better than foveal vision due to the low distribution-density of rods in the central part of the human eye. However, rods are about two-and-a-half times more sensitive than cones (Fig. 5.3, after data published by ) szechy and Stiles, 1982, p. 256). They do not contribute to photopic vision because of over-exposure when illumination is high (a process called bleaching). 

Keywords Foveal vision Peripheral vison Optical flow Combined fields of view Ergonomics Safety Commercial vehicles Camera monitor system Mirror replacement... 

Antidepressants Noradrenaline/5-HT transporters Na+, K+ channels l Noradrenaline/ 5-HT reuptake l Na+ currents t K+ currents l Excitability of peripheral and central neurons Cardiac arrhythmia, myocardial infarction, sedation, nausea, dry mouth, constipation, dizziness, sleep disturbance, blurred vision... 

Neurological signs nystagmus, miosis, blurred vision, tremor, slurred speech, dystonia, convulsion, amnesia, confusion, peripheral numbness... 

The ammonia produced by enteric bacteria and absorbed into portal venous blood and the ammonia produced by tissues are rapidly removed from circulation by the liver and converted to urea. Only traces (10—20 Ig/dL) thus normally are present in peripheral blood. This is essential, since ammonia is toxic to the central nervous system. Should portal blood bypass the liver, systemic blood ammonia levels may rise to toxic levels. This occurs in severely impaired hepatic function or the development of collateral links between the portal and systemic veins in cirrhosis. Symptoms of ammonia intoxication include tremor, slurred speech, blurred vision, coma, and ultimately death. Ammonia may be toxic to the brain in part because it reacts with a-ketoglutarate to form glutamate. The resulting depleted levels of a-ketoglutarate then impair function of the tricarboxylic acid (TCA) cycle in neurons. 

Antimuscarinic drugs such as atropine have been used to modest effect in the treatment of PD for more than a century attenuating tremor and rigidity but with little effect on akinesia. Currently benzhexol and benztropine are sometimes added to levodopa therapy but peripheral effects such as dry mouth, blurred vision and constipation are unpleasant. They are also often used to counteract neuroleptic-induced extrapyramidal effects. 

Severe, acute respiratory acidosis produces a variety of neurologic abnormalities. Initially these include headache, blurred vision, restlessness, and anxiety. These may progress to tremors, asterixis, somnolence, and/or delirium. If untreated, terminal manifestations include peripheral vasodilation leading to hypotension and cardiac arrhythmias. Chronic respiratory acidosis is typically associated with cor pulmonale and peripheral edema. 

Headache and compromised visual function (loss of peripheral vision and blurred vision) caused by the actual tumor mass and its close proximity to the optic structures. 

Patients with severe disease progression may report loss of peripheral vision and may describe the presence of scotomata (blind spots) in their field of vision. 

Nasal scotoma An area of blindness in the nasal portion of peripheral vision. 

Wooten, B. R. and G. Wald (1973). Color-vision mechanisms in the peripheral retinas of normal and dichromatic observers. Journal of General Physiology 61 125-145. 

A 65-year-old male complains of losing his vision Retinal examination reveals optic nerve cupping. Peripheral vision loss is observed on visual field tests, and his intraocular pressure is increased. Following treatment with a drug, he has improved visual acuity and decreased intraocular pressure. 

Mutations in rhodopsin and other photoreceptor proteins are linked to retinitis pigmentosa. Retinitis pigmentosa (RP) is a group of inherited retinopathies that affects about 1 in 4,000 humans [26], RP maybe classified into four types autosomal dominant (19%), autosomal recessive (19%),X-linked (8%) and allied diseases (54%). RP is characterized by loss of night vision in the early stage, followed by loss of peripheral vision. Chromosomal loci for numerous RP genes have been mapped and mutations characterized [27]. 

Common but usually transient side effects are lethargy, incoordination, blurred vision, higher cortical dysfunction, and drowsiness. At concentrations greater than 50 mcg/mL, phenytoin can exacerbate seizures. Chronic side effects include gingival hyperplasia, impaired cognition, hirsutism, vitamin D deficiency, osteomalacia, folic acid deficiency, carbohydrate intolerance, hypothyroidism, and peripheral neuropathy. 

The onset of botulism occurs generally between 18 and 36 hours after consumption of food products containing botulin toxin. However, it may affect patients earlier or later, even on the tenth day after food consumption. The first symptoms include stomach ache, nausea, vomiting, and diarrhea, followed by neurological disorders. Other symptoms include, skin, mouth and throat dryness, diplopia, blurred vision, dysphonia, dysarthria, dysphagia, and peripheral weakness. In lethal cases of botulism, respiratory muscles are involved. This leads to respiratory failure and death. Because all the symptoms are connected with toxemia, the first step of medical treatment is to provide a patient with antiserum. 

As an inhibitor of plasma (pseudo) cholinesterase, DFP produced only minimal reversal of scopolamine-induced incapacitation. Note the very low plasma ChE levels, with only minor decreases in RBC ChE (Fig. 71). DFP does improve near vision when applied to the eye (David Flarper, unpublished data) suggesting that paralysis of the muscles of visual accommodation is probably peripheral in origin. Persistence of pupillary enlargement (in the face of systemic treatment with physostigmine) may be due to physiological or pK factors, causing limited access to the iris. 

Other effects on humans from inhalation of various concentrations are as follows 2000 ppm, mild central nervous system depression within 5 minutes 600 ppm, sensation of numbness around the mouth, dizziness, and some incoordination after 10 minutes. In human experiments, 7-hour exposures at 100 ppm resulted in mild irritation of the eyes, nose, and throat flushing of the face and neck headache somnolence and slurred speech. Prolonged exposure has caused impaired memory, numbness of extremities, and peripheral neuropathy, including impaired vision. ... 

Adverse reactions occurring in at least 3% of patients include abnormal dreams, abnormal vision, asthenia, blurred vision, confusion, constipation, cough, decreased concentration, diarrhea, dizziness, dry mouth, dyspepsia, flu syndrome, headache, increased appetite, infection, insomnia, lightheadedness, memory impairment, nausea, paresthesia, peripheral edema, pharyngitis, postural hypotension, somnolence, vasodilation. 

---